Table 2. Enhancement of the viral inactivation activity of the gp120-targeting proteins against laboratory-adapted HIV-1 virions in the absence (alone) or presence (in mixture) of gp41-targeting fusion inhibitor T20, T2635 or SFT.

Combined with	2Dm2m			4Dm2m
	EC50 (nM)		Enhancement (fold)	EC50 (nM)		Enhancement (fold)
	Alone	In mixture		Alone	In mixture
HIV-1IIIB (B, X4)
T20	0.99	0.23	4.3	0.39	0.06	6.5
T2635	0.99	0.21	4.7	0.39	0.10	3.9
SFT	0.99	0.61	1.6	0.39	0.15	2.6
HIV-1Bal (B, R5)
T20	1.29	0.24	5.4	0.27	0.11	2.5
T2635	1.29	0.34	3.8	0.27	0.11	2.5
SFT	1.29	0.93	1.4	0.27	0.17	1.6

Data are representative of testing in triplicate (mean).